FuelCell Energy Inc vs Dr. Reddy's Laboratories Ltd Common Stock — how do they compare? FuelCell Energy Inc trades at $13.83 (market cap $1.24B), while Dr. Reddy's Laboratories Ltd Common Stock trades at $12.75 (market cap $10.78B). The key difference: Dr. Reddy's Laboratories Ltd Common Stock is far larger — about 8.7× FuelCell Energy Inc's market cap, and Dr. Reddy's Laboratories Ltd Common Stock pays a 0.65% dividend while FuelCell Energy Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold FuelCell Energy Inc for 48 Days and Dr. Reddy's Laboratories Ltd Common Stock for 0 Days on average.
| FCEL | RDY | |
|---|---|---|
Market Cap | $1.24B | $10.78B |
Volume | 7,483,477 | 2,724,343 |
Sector | Industrials | Health |
52-Week High | $36.01 | $15.38 |
52-Week Low | $6.00 | $11.38 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | $818.79M | $10.68B |
Dividend Yield | — | 0.65% |
Signals from Pluang's Aura AI — not financial advice
FCEL trades at $15.495, down 5.35% today, with a bearish technical signal and mixed analyst ratings. The company shows persistent losses, with a net income margin of -113.6% in 2025, though revenue grew to $158.16M. Recent news highlights a securities class action lawsuit and a brief stock rally, reflecting high volatility and investor uncertainty amid ongoing financial challenges.
The outlook remains cautious due to sustained unprofitability and legal risks, but analyst consensus targets $21.57 suggest potential upside if execution improves. Key risks include cash burn, competitive pressures, and the outcome of litigation, requiring careful risk assessment for investors considering exposure to this speculative energy stock.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →Dr. Reddy's Laboratories Ltd. develops and manufactures generic medicines, active pharmaceutical ingredients (APIs), biosimilars, and over-the-counter (OTC) products, headquartered in Hyderabad, India, with therapeutic focus areas spanning gastrointestinal, cardiovascular, oncology, and dermatology.
Read more on RDY →